Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication.
RSV
SARS-CoV-2
antiviral
influenza virus
replication
repurposed
respiratory virus
screens
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
received:
08
02
2022
revised:
08
03
2022
accepted:
14
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Viral replication and transmissibility are the principal causes of endemic and pandemic disease threats. There remains a need for broad-spectrum antiviral agents. The most common respiratory viruses are endemic agents such as coronaviruses, respiratory syncytial viruses, and influenza viruses. Although vaccines are available for SARS-CoV-2 and some influenza viruses, there is a paucity of effective antiviral drugs, while for RSV there is no vaccine available, and therapeutic treatments are very limited. We have previously shown that probenecid is safe and effective in limiting influenza A virus replication and SARS-CoV-2 replication, along with strong evidence showing inhibition of RSV replication in vitro and in vivo. This review article will describe the antiviral activity profile of probenecid against these three viruses.
Identifiants
pubmed: 35337018
pii: v14030612
doi: 10.3390/v14030612
pmc: PMC8955960
pii:
doi:
Substances chimiques
Probenecid
PO572Z7917
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
PLoS One. 2021 Oct 29;16(10):e0259129
pubmed: 34714852
Viruses. 2012 Nov 06;4(11):2786-805
pubmed: 23202505
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):
pubmed: 33766889
Immunity. 2021 Aug 10;54(8):1715-1727.e7
pubmed: 34283971
Pharmacol Ther. 2021 Dec;228:107930
pubmed: 34174275
Clin Infect Dis. 2020 May 6;70(10):2238-2239
pubmed: 31504299
Viruses. 2020 Apr 14;12(4):
pubmed: 32295124
Expert Opin Pharmacother. 2001 Aug;2(8):1317-24
pubmed: 11585000
J Gen Virol. 2021 May;102(5):
pubmed: 34020727
Pharmacol Ther. 2012 Oct;136(1):106-30
pubmed: 22841915
Emerg Infect Dis. 2018 Sep;24(9):1696-1699
pubmed: 29882740
Front Pharmacol. 2021 Nov 18;12:704205
pubmed: 34867318
Rev Med Virol. 2018 Mar;28(2):
pubmed: 29377415
mSystems. 2021 Oct 26;6(5):e0038821
pubmed: 34519533
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1766-1772
pubmed: 34968374
JAMA. 2022 Jan 18;327(3):211-212
pubmed: 34989789
Physiol Rev. 2015 Jan;95(1):83-123
pubmed: 25540139
Sci Rep. 2021 Sep 10;11(1):18085
pubmed: 34508172
Life (Basel). 2021 Feb 05;11(2):
pubmed: 33562645
MMWR Recomm Rep. 2020 Aug 21;69(8):1-24
pubmed: 32820746
J Biol Chem. 2022 Feb;298(2):101529
pubmed: 34953856
Virology. 2005 Feb 5;332(1):20-7
pubmed: 15661137
Antiviral Res. 2022 Feb;198:105252
pubmed: 35085683
Mol Syst Biol. 2020 Jul;16(7):e9628
pubmed: 32729248
Immunol Cell Biol. 2005 Jun;83(3):217-23
pubmed: 15877598
Expert Opin Drug Saf. 2019 Apr;18(4):261-271
pubmed: 30915866
J Biomed Biotechnol. 2006;2006(4):45716
pubmed: 17057364
Eur J Pharm Sci. 2021 Jul 1;162:105814
pubmed: 33753216
FASEB J. 2012 Apr;26(4):1372-86
pubmed: 22247330
Nat Rev Drug Discov. 2022 Jan;21(1):3-5
pubmed: 34857884
Am J Physiol Cell Physiol. 2008 Sep;295(3):C761-7
pubmed: 18596212
Int J Med Microbiol. 2014 Jul;304(5-6):725-9
pubmed: 24938792
Influenza Other Respir Viruses. 2018 Jan;12(1):132-137
pubmed: 29446233
Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S218-S228
pubmed: 34472577
Sci Data. 2017 Mar 01;4:170021
pubmed: 28248921
Toxicology. 2013 Sep 15;311(3):135-46
pubmed: 23856525
Sci Rep. 2021 Sep 30;11(1):19443
pubmed: 34593846
Viruses. 2021 Dec 10;13(12):
pubmed: 34960746
Eur J Med Chem. 2017 Jul 28;135:467-478
pubmed: 28477572
PLoS One. 2018 Mar 22;13(3):e0194880
pubmed: 29566079
Viruses. 2021 Apr 06;13(4):
pubmed: 33917411
Ann Med. 2022 Dec;54(1):516-523
pubmed: 35118917
PLoS One. 2021 Apr 22;16(4):e0250019
pubmed: 33886614
Nat Immunol. 2022 Feb;23(2):194-202
pubmed: 35105985
Semin Respir Crit Care Med. 2011 Aug;32(4):423-32
pubmed: 21858747
Influenza Other Respir Viruses. 2019 Mar;13(2):138-147
pubmed: 30596225
Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S229-S237
pubmed: 34472576
Physiol Rev. 2002 Oct;82(4):1013-67
pubmed: 12270951
J Infect. 2021 Aug;83(2):182-189
pubmed: 34081957
Front Pharmacol. 2021 Mar 25;12:646676
pubmed: 33841165
Expert Opin Investig Drugs. 2020 Mar;29(3):285-294
pubmed: 32096420
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):132-138
pubmed: 35085223
Drug Resist Updat. 2021 Dec;59:100794
pubmed: 34991982
EMBO J. 2006 Nov 1;25(21):5071-82
pubmed: 17036048
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
Med Chem Res. 2022 Jan 3;:1-12
pubmed: 35002192
Pharmacol Rep. 2020 Dec;72(6):1479-1508
pubmed: 32889701
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
Biochim Biophys Acta Biomembr. 2018 Jan;1860(1):72-82
pubmed: 28279657
Methods. 2015 Dec;91:75-81
pubmed: 26164699
iScience. 2021 Dec 17;24(12):103478
pubmed: 34841222
J Cell Sci. 2007 Nov 1;120(Pt 21):3772-83
pubmed: 17925379
PLoS One. 2017 Nov 27;12(11):e0188333
pubmed: 29176782
Vaccine X. 2019 Oct 08;3:100045
pubmed: 31660537
Expert Opin Ther Pat. 2021 Oct;31(10):911-936
pubmed: 33971786
Pharmaceuticals (Basel). 2013 Jan 28;6(2):124-60
pubmed: 24275945
Viruses. 2021 Apr 13;13(4):
pubmed: 33924302
Antimicrob Agents Chemother. 2013 Jan;57(1):475-83
pubmed: 23129053
Annu Rev Public Health. 2022 Jan 4;:
pubmed: 34982587
Br J Pharmacol. 2019 Oct;176(19):3834-3844
pubmed: 31271646
J Virol. 2017 May 26;91(12):
pubmed: 28381577
Antiviral Res. 2020 Jun;178:104805
pubmed: 32330482
Curr Opin Pediatr. 1994 Feb;6(1):17-22
pubmed: 8205168
Ann Intern Med. 2021 Nov;174(11):ITC161-ITC176
pubmed: 34748378
Pharm Res. 2007 Mar;24(3):450-70
pubmed: 17245646
Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L121-L125
pubmed: 32519892
Methods Mol Biol. 2011;721:397-405
pubmed: 21431700
Curr Opin Virol. 2021 Dec;51:216-223
pubmed: 34781106